• FOXM1–ERα ceRNA Network: Mechanistic Insights in Female LUAD

  2026-05-05

  This study identifies and validates a novel ceRNA network involving FOXM1 and estrogen receptor 1 (ERα) in female lung adenocarcinoma (LUAD), integrating transcriptomic and in vitro analyses. The findings reveal new mechanistic links between lncRNAs, miRNAs, and ERα signaling, with implications for biomarker discovery and immunotherapy response prediction.

• SB 431542: ALK5 Inhibitor Optimizes TGF-β Signaling Studies

  2026-05-04

  SB 431542 from APExBIO offers unmatched selectivity for ALK5, empowering researchers to dissect TGF-β pathway roles in fibrosis, tumor immunology, and cell differentiation. This guide provides advanced experimental workflows and troubleshooting strategies tailored for reproducible, high-impact results.

• LY294002: Precision PI3K/Akt/mTOR Inhibition in Neuroinflamm

  2026-05-04

  Explore how LY294002, a potent PI3K/Akt/mTOR signaling pathway inhibitor, uniquely advances neuroinflammation and depression research through rigorous mechanistic analysis and translational insights. Discover optimized protocols and nuanced comparisons with alternative strategies.

• Substance P: Advanced Workflows for Pain and Inflammation Re

  2026-05-03

  Unlock the full potential of Substance P in CNS and immune studies with protocol-driven insights and troubleshooting strategies. Learn how spectral innovations and workflow refinement empower reproducible pain transmission and inflammation research using APExBIO’s high-purity tachykinin neuropeptide.

• BMS 309403: Applied Protocols for FABP4 Inhibition in Athero

  2026-05-02

  BMS 309403 delivers precise, selective inhibition of FABP4, enabling advanced workflows for dissecting lipid metabolism and inflammation in atherosclerosis research. This guide details optimized protocols, troubleshooting approaches, and actionable insights grounded in recent findings on the CaN/FoxO1/FABP4 pathway.

• Norovirus Hijacks NINJ1 for Selective NS1 Protein Secretion

  2026-05-01

  Song et al. reveal that murine norovirus co-opts the host protein NINJ1 to selectively secrete its NS1 protein through a caspase-3-dependent, unconventional pathway. This finding redefines our understanding of regulated plasma membrane rupture and viral manipulation of host cell death machinery, with implications for studying secretion and immune evasion in viral infections.

• Precision Use of BPN-19186 in sEH-Nrf2 Pathway Assays: A Res

  2026-05-01

  (S)-1-(3-fluoro-4-(trifluoromethoxy)phenyl)-3-(1-(2-methylbutanoyl)piperidin-4-yl)urea (BPN-19186) enables advanced, reproducible sEH-Nrf2 signaling research. Discover protocol guidance, mechanistic insights, and expert analysis for optimizing biochemical and disease-model assays.

• SARS-CoV-2 N Protein Suppresses GADD34-Mediated Innate Immun

  2026-04-30

  This study uncovers how the SARS-CoV-2 nucleocapsid protein disrupts innate immune signaling by sequestering GADD34 mRNA into atypical stress granule-like foci, ultimately impairing interferon responses. The mechanistic insights offer new directions for antiviral research and targeted modulation of cellular stress pathways.

• Dihydrotestosterone (DHT): Precision Tools for AR Signaling

  2026-04-30

  Dihydrotestosterone (DHT) is redefining research on androgen receptor signaling, EGFR/ERBB2 pathways, and therapeutic resistance mechanisms in cancer and neuromuscular models. Leveraging APExBIO's high-purity DHT, advanced workflows enable reproducible modulation of signaling cascades and empower troubleshooting in complex in vitro and in vivo settings.

• Refining In Vitro Drug Response Metrics in Cancer Research

  2026-04-29

  This dissertation by Hannah R. Schwartz rigorously dissects how distinct in vitro metrics—relative viability and fractional viability—capture different facets of anti-cancer drug responses, challenging the practice of using them interchangeably. By clarifying how drugs variably affect proliferation and cell death, the work delivers a practical framework for interpreting drug efficacy in preclinical cancer models.

• AP20187 in Conditional Gene Therapy: Precision by Design

  2026-04-29

  Explore how AP20187, a leading chemical inducer of dimerization, enables next-generation control in conditional gene therapy. This article uniquely integrates mechanistic insight with advanced assay design and practical guidance for translational research.

• UGDH Phosphorylation Drives Glycosaminoglycan Synthesis and

  2026-04-28

  This study reveals that phosphorylation of UDP-glucose dehydrogenase (UGDH) at serine 316 by AGC kinases reprograms glycosaminoglycan biosynthesis in prostate cancer cells, promoting motility, spheroid growth, and resistance to enzalutamide. These findings highlight a novel metabolic mechanism of therapeutic resistance with direct implications for castration-resistant prostate cancer research.

• Ganetespib (STA-9090) in Cancer Research: Applied Protocols

  2026-04-28

  Ganetespib (STA-9090) stands out for its rapid, high-affinity Hsp90 inhibition and broad antitumor efficacy in both cellular and animal models. This guide details evidence-backed workflows, advanced troubleshooting, and strategic opportunities to optimize experimental results with this triazolone-based small molecule—empowering translational oncology research.

• Imatinib Hydrochloride: Advanced Tyrosine Kinase Inhibitor W

  2026-04-27

  Imatinib hydrochloride (STI571 hydrochloride) offers multi-target kinase inhibition for robust cancer research, streamlining workflows in CML and GIST models. This guide translates recent dual-action mechanistic insights into protocol-level advantages, troubleshooting, and assay optimization.

• GPR30 in Spinal CCK+ Neurons: A Key Modulator of Neuropathic

  2026-04-27

  This study establishes spinal GPR30 (GPER) expression in cholecystokinin-positive (CCK+) neurons as a critical driver of neuropathic pain. By combining molecular, electrophysiological, and chemogenetic approaches, the research provides mechanistic insight into how GPR30-mediated signaling shapes pain circuits and highlights new intervention targets.

16255 records 1/1084 page Next 12345 下5页 Last page